Treatment patterns and use of healthcare resources of patients with atherosclerotic cardiovascular disease and hypercholesterolemia and patients with familial hypercholesterolemia in Spain: Protocol of the Reality study

Vivencio Barrios1,2*, Mar Castellanos3,4, Raquel Campuzano Ruiz5, Jorge Francisco Gómez Cerezo6, Isabel Egocheaga Cabello7, José M. Gámez8,9, Icíar Martínez López10, José María Mostaza11, Nuria Morant Talamante12, Javier Parrondo13, Aram Sicras Navarro14, Inés Pérez Román15, Antoni Sicras-Mainar14 and Vicente Pallarés-Carratalá16,17

Background: Atherosclerotic cardiovascular diseases (ASCVD) and dyslipidemia are associated to a higher risk of cardiovascular events, mortality, use of healthcare resources and costs. In Spain, the evidence about the administration of lipid-lowering treatments in clinical practice, and their clinical effectiveness in patients with ASCVD and hypercholesterolemia and patients with FH is scarce. Therefore, a multidisciplinary working group of cardiologists, family physicians, internal medicine specialists and neurologists was gathered for the Reality study. The aim of this study is to describe the demographic and clinical characteristics, comorbidities, and concomitant medication of patients with ASCVD and hypercholesterolemia and of patients with familial hypercholesterolemia (FH). The use of healthcare resources and

OPEN ACCESS

EDITED BY
Nathalie Pamir,
Oregon Health and Science University,
United States

REVIEWED BY
Ghada Youssef,
Cairo University, Egypt
Mariann Harangi,
University of Debrecen, Hungary

*CORRESPONDENCE
Vivencio Barrios
vivencio.barrios@gmail.com

SPECIALTY SECTION
This article was submitted to Lipids in Cardiovascular Disease, a section of the journal Frontiers in Cardiovascular Medicine

RECEIVED 10 June 2022
ACCEPTED 18 July 2022
PUBLISHED 04 August 2022

CITATION
Barrios V, Castellanos M, Campuzano Ruiz R, Gómez Cerezo JT, Egocheaga Cabello I, Gámez JM, Martínez López I, Mostaza JM, Morant Talamante N, Parrondo J, Sicras Navarro A, Pérez Román I, Sicras-Mainar A and Pallarés-Carratalá V (2022) Treatment patterns and use of healthcare resources of patients with atherosclerotic cardiovascular disease and hypercholesterolemia and patients with familial hypercholesterolemia in Spain: Protocol of the Reality study. Front. Cardiovasc. Med. 9:966049. doi: 10.3389/fcvm.2022.966049

COPYRIGHT © 2022 Barrios, Castellanos, Campuzano Ruiz, Gómez Cerezo, Egocheaga Cabello, Gámez, Martínez López, Mostaza, Morant Talamante, Parrondo, Sicras Navarro, Pérez Román, Sicras-Mainar and Pallarés-Carratalá. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Atherosclerosis is the most frequent cause of cardiovascular disease in adults, which is one of the main risk factors of coronary disease in adults (3, 6, 7). The prevention and control of these diseases will also be estimated. Due to the high morbidity and mortality associated with these diseases, it is expected that our study will provide useful information for healthcare systems and decision makers to improve the management of these disabling diseases.

KEYWORDS
hypercholesterolemia, atherosclerosis, hypolipidemic agents, health resources, health care costs

Introduction

Cardiovascular (CV) diseases are due to disorders of the heart and blood vessels, such as myocardial infarction, ischemic cardiopathy, cerebrovascular accident and peripheral artery disease (1, 2). Atherosclerosis is the most frequent cause of vascular disease (3), and is usually related to lifestyle and biochemical and physiological modifiable factors like excess weight or high blood pressure or high lipid levels (4). The reduction of CV risk may decrease the morbidity and mortality associated with ASCVD (1, 3), which constitutes one of the main causes of morbimortality and premature deaths in developed countries (1, 2), leading to a high use of resources and costs for healthcare systems (3–5).

Dyslipidemia is caused by abnormal levels of lipoproteins in blood, which is one of the main risk factors of coronary disease in adults (3, 6, 7). The prevention and control of these diseases is critical for healthcare systems (1, 6, 7). The aim of secondary prevention is to stabilize the atherosclerotic plaque, by reducing the inflammation, the risk of rupture and the subsequent thrombosis (1, 3). The pharmacological treatment is one of the main components of the therapy; lipid-lowering drugs, particularly statins (HMG-CoA reductase inhibitors), have shown to reduce CV risks (1, 2, 7, 8). In addition, several studies showed that in patients who received treatments for secondary prevention, the lower the blood levels of lipoproteins of low density (LDL) are, the better prognosis patients have (9). In this sense, a meta-analysis showed that major CV events (major coronary events, coronary revascularization, or stroke) were reduced by 22% (non-fatal ischemic stroke, 23%; deaths due to coronary disease, 20%; deaths due to other cardiac causes, 11%) for 5 years per each 1 mmol/L reduction in LDL (3, 10).

Despite these results, the percentage of patients who meet the definition of LDL control is still low (3, 11–14). The EUROASPIRE study (14) showed that in patients who had suffered a coronary event, 71% of them had LDL levels ≥70 mg/dL, while 37% of them had LDL levels ≥100 mg/dL. In addition, the Da Vinci study confirmed that only 18% of patients on secondary prevention treatments reach LDL levels <1.4 mmol/L (55 mg/dL) (15). In this sense, some groups of patients may have difficulties to achieve the therapeutic goals, such as those diagnosed with familial hypercholesterolemia (FH), those with partial or total intolerance to statins and/or very-high CV risk. Although statins are safe and well tolerated, their use at high doses and/or their long-term administration may increase the risk of adverse events, like elevated transaminase levels or myopathies. The lack of LDL control is associated with the inadequacy of treatment, the lack of efficacy of lipid-lowering drugs combinations and the low adherence to medication (11, 13, 16, 17).

In Spain, the evidence available about the administration of lipid-lowering treatments in clinical practice, and their clinical effectiveness in patients with ASCVD and hypercholesterolemia and patients with FH is scarce. However, this information is likely to be of particular interest for healthcare systems, along with the analysis of the use of healthcare resources and the
treatment and follow-up costs of these patients. Therefore, a multidisciplinary working group of cardiologists, family physicians, internal medicine specialists and neurologists was gathered for the Reality study.

Methods and analysis

Study design

The Reality study is an observational and retrospective analysis, based on electronic medical registries (EMR) from the BIG-PAC® database (18). This database includes the EMR of 1.8 million people from 7 health areas (including public primary care centers and hospitals) of 7 Autonomous Communities in Spain. EMR are anonymized in the source centers, according to the Organic Law 3/2018, 5th December of Protection of personal data and guarantee of digital rights (19). The BIG-PAC® database is representative of the Spanish population (20).

Objectives

The primary objective is to describe the demographic and clinical characteristics, comorbidities, and concomitant medications of patients with ASCVD and hypercholesterolemia and of patients with FH. The secondary objectives are (1) to describe the lipid-lowering treatment to reduce cholesterol in patients with ASCVD and hypercholesterolemia and patients with FH, (2) to describe the treatment modifications, the reasons for change, and the medication persistence during the follow-up period, along with the characteristics of non-adherent patients (medication possession ratio [MPR] <80%), (3) to evaluate the LDL levels during the follow-up period, according to the intensity of the lipid-lowering treatment, (4) to estimate the prevalence and the incidence rates of ASCVD and FH, (5) to estimate the use of healthcare resources and costs during the follow-up period and (6) to estimate the utilization of healthcare resources in primary care centers and hospitals during the follow-up period. The exploratory objectives include estimating the percentage of patients who are intolerant to statins and to assess the use of resources and costs associated with ASCVD and FH, according to the intensity of the lipid-lowering treatment and the LDL levels.

Study population

The study includes patients who had a new or recurrent episode of ASCVD during the recruitment period (from 01/01/2017 to 31/12/2018). The index date will be defined as the date of the ASCVD event, and the follow-up period is 24 months after the index date. If a patient with recurrent events suffers an ASCVD event during the recruitment period, the date of the first event during that period will be considered as the first event. The diagnoses of ASCVD and hypercholesterolemia will be obtained from the International Classification of Diseases, 9th edition, Clinical Modification (ICD-9-CM) (21) coding system: (1) stable/unstable angina (codes: 411, 413), (2) acute myocardial infarction (AMI) (codes: 410, 412), (3) ischemic stroke (codes: 433, 434, 436), (4) transient ischemic attack (TIA, code: 435), (5) peripheral arterial disease (PAD, codes: 440 - 441, 444) and (6) FH (code: 272.0). Patients will be classified as ASCVD (5 groups) or FH, according to their first diagnosis in the database.

The diagnostic criteria are based on the patients’ symptoms, in agreement with medical practice. In addition, diagnostic tests are used to detect structural or functional abnormalities in the heart, brain, kidney, or blood vessels.

The inclusion criteria are (a) age ≥18 years; (b) diagnosis of ASCVD or FH during the recruitment period; (c) being active in the database (defined as having ≥2 records at least 6 months before the index date; (d) having ≥2 records during the follow-up period and (e) patients with ASCVD should have at least a record of LDL ≥70 mg/dL at any time before or 3 months after the index date, diagnosis of hypercholesterolemia or lipid-lowering treatments. Patients who are not correctly identified in the database (e.g., birth date or sex have not been recorded) are not included in the study.

Subgroups

Regardless of their first diagnosis in the database, patients with ASCVD and hypercholesterolemia will be divided into (1) those who received statins, (2) those who were not on treatment with statins, and (3) those who were on other treatments to reduce cholesterol. The ability of the lipid-lowering treatment to reduce cholesterol (extreme, very high, high and moderate) will be also analyzed. Patients will be further classified considering their LDL levels at the time they received a ASCVD diagnosis after the earliest statin prescription. The cutoff values will be 55 mg/dL, 70 mg/dL and 100 mg/dL.

Patients with FH will be classified in (1) patients who were treated with statins, (2) patients who were not on treatment with statins and (3) patients who received other treatments to reduce cholesterol. The ability of the treatment with statins to reduce cholesterol will be also analyzed. Patients with FH will be classified according to their LDL levels at the time they received a FH diagnosis after the earliest statin prescription. The cutoff points of 55 mg/dL, 70 mg/dL and 100 mg/dL will be considered. Patients with FH will be further divided
TABLE 1 Classification of lipid-lowering drugs according to their ability to reduce cholesterol.

| Lowering ability | Treatments |
|------------------|------------|
| Extreme          | Evolocumab 140 mg |
|                  | Alirocumab 75 mg |
|                  | Alirocumab 150 mg |
| Very high        | Potent statin + ezetimibe |
|                  | Atorvastatin 40–80 mg + ezetimibe 10 mg |
|                  | Rosuvastatin 10–40 mg + ezetimibe 10 mg |
| High             | High-potency statin |
|                  | Atorvastatin 40–80 mg |
|                  | Rosuvastatin 20–40 mg |
|                  | Medium-potency statin + ezetimibe |
|                  | Simvastatin 20–40 mg + ezetimibe 10 mg |
|                  | Pravastatin 40 mg + ezetimibe 10 mg |
|                  | Lovastatin 40 mg + ezetimibe 10 mg |
|                  | Fluvastatin 80 mg + ezetimibe 10 mg |
|                  | Pitavastatin 2–4 mg + ezetimibe 10 mg |
|                  | Atorvastatin 10–20 mg + ezetimibe 10 mg |
|                  | Rosuvastatin 5 mg + ezetimibe 10 mg |
| Moderate         | Medium-potency statin |
|                  | Atorvastatin 10–20 mg |
|                  | Rosuvastatin 5–10 mg |
|                  | Simvastatin 20–40 mg |
|                  | Pravastatin 40 mg |
|                  | Lovastatin 40 mg |
|                  | Fluvastatin 2–4 mg |
|                  | Fluvastatin XL 80 mg |
| Low-potency statin + ezetimibe | Simvastatin 10 mg + ezetimibe 10 mg |
|                  | Pravastatin 20 mg + ezetimibe 10 mg |
|                  | Lovastatin 20 mg + ezetimibe 10 mg |
|                  | Fluvastatin 40 mg + ezetimibe 10 mg |
|                  | Pitavastatin 1 mg + ezetimibe 10 mg |

Source: Escobar et al. (22).

TABLE 2 Diagnoses included for the calculation of the Charlson comorbidity index, and their corresponding ICD-09-CM codes.

| ICD-09-CM codes | Condition | Score |
|----------------|-----------|-------|
| 410 – 410.9, 412 | Myocardial infarction | 1 |
| 428 – 428.9 | Congestive heart failure | 1 |
| 433.9, 441 – 441.9, 785.4, V43.4 | Peripheral vascular disease | 1 |
| 430 – 438 | Cerebrovascular disease | 1 |
| 290 – 290.9 | Dementia | 1 |
| 490 – 496, 500 – 505, 506.4 | Chronic pulmonary disease | 1 |
| 710.0, 710.1, 710.4 – 714.2, 714.8 | Rheumatologic disease | 1 |
| 513 – 534.9 | Pecopt ulcer disease | 1 |
| 571.2, 571.5, 571.6, 571.4 – 571.49 | Mild liver disease | 1 |
| 250 – 250.3, 250.7 | Diabetes | 1 |
| 250.4 – 250.6 | Diabetes with chronic complications | 2 |
| 344.1, 342 – 342.9 | Hemiplegia or paraplegia | 2 |
| 582 – 582.9, 583 – 583.7, 585, 586, 588 – 588.9 | Kidney disease | 2 |
| 140 – 172.9, 174 – 195.8, 200 – 208.9 | Any malignancy, including leukemia and lymphoma | 2 |
| 572.2 – 572.8 | Moderate or severe liver disease | 3 |
| 196 – 199.1 | Metastatic solid tumor | 6 |
| 042 – 044.9 | AIDS | 6 |

ICD-9-CM, International Classification of Diseases, 9th edition, Clinical Modification. Source: Charlson et al. (23) and Deyo et al. (24).

in homozygous (HoFH) and heterozygous (HeFH), and per age range.

Data

Demographic characteristics and comorbidities

At the index date, the following variables will be considered: age (continuous and in ranges: 18–24; 25–34; 35–44; 45–54; 55–64; 65–75; and ≥75 years), and sex.

The comorbidities of the study population will be recorded from the medical records, during the 6 months before the index date, using the ICD-9-CM coding system. The study includes the collection of cardiovascular comorbidities (arterial hypertension, atrial fibrillation [persistent, paroxysmal, and permanent/chronic]), valvulopathies (stenosis or insufficiency [aortic or mitral]), carotid stenosis, heart failure, and angina (stable/unstable) (codes: 411, 413), AMI (codes: 410, 412), atherosclerotic aortic disease, ischemic stroke (codes: 433, 434, 436), TIA (code: 435), PAD (intermittent claudication, ischemia arterial) (codes: 440–441, 444) and atherosclerotic disorders not included in the index diagnosis. Other comorbidities will be considered, such as diabetes mellitus, obesity, chronic alcoholism, hypercholesterolemia, hypertriglyceridemia, mixed dyslipidemia, chronic renal disease (stages II, IIIa, IIIb, IV and V), hepatic disease (cirrhosis, encephalopathy, cholangitis sclerosing, liver cancer), fatty liver, chronic obstructive pulmonary disease (COPD), obstructive sleep apnea syndrome (OSAS), dementia/cognitive impairment (including Alzheimer’s disease), depressive disorder, malignancies, anemia, rheumatoid arthritis, and statin intolerance. In addition, the Charlson comorbidity index (23) will be used as a summary variable of the severity status of patients (Table 2). The number of patients who smoke and the corresponding percentages in each cohort will be estimated.
Prevalence and incidence rates

Prevalence rates of ASCVD and FH will be estimated as the overall number of cases diagnosed with ASCVD or FH in the assisted population (≥18 years), during two consecutive years (2017 and 2018). Incidence rates will be calculated as the number of new cases diagnosed per 1,000 patients/year during those years. Due to the similarities of our database with the Spanish population pyramid, in terms of age and sex (20), these results will not be standardized. Prevalence and incidence rates will be provided per type of ASCVD or FH, age range (18–44 years, 45–64 years and ≥65 years) and sex. In addition, prevalence rates will be estimated by year.

Biochemical and anthropometric parameters

Other parameters of the study population will be collected, such as body mass index (BMI), systolic arterial pressure (SAP), diastolic arterial pressure (DAP), cholesterol, very low-density lipoproteins (VLDL), LDL, high-density lipoproteins (HDL), triglycerides, and glycoside hemoglobin (HbA1c) in diabetic patients. The levels of glutamic oxaloacetic transaminase (GOT), glutamic-pyruvic transaminase (GPT), alkaline phosphatase, and lipoprotein (a) will also be considered. These values will be analyzed at the index date, at 12 months and 24 months of follow-up.

Patients will be classified according to their LDL values at the index date into <55, 55–69, 70–99, and ≥100 mg/dL. In addition, the absolute (mg/dL) and relative variation (%) of the LDL levels from the index date to the last record available will be estimated. Patients with LDL levels below 55 mg/dL at the end of the study will be estimated (3). Other cutoff values will be 70 and 100 mg/dL.

Treatment: Procedures

The study considers the therapeutic procedures that patients had received in the 6 months before the index date. These procedures are dialysis, lipoprotein apheresis, coronary artery bypass, percutaneous coronary intervention, carotid revascularization (angioplasty without stent/endarterectomy) and thrombectomy.

Treatment: Lipid-lowering medication

The use of lipid-lowering medication will be obtained from the dispensation records, using the Anatomical Therapeutic Chemical Classification System (ATC) codes (25). Drugs were prescribed according to medical practice. Drug groups were fibrates (C10AB), bile acid sequestrants (C10AC) nicotinic acid (C10AD), and other lipid-modifying agents like PCSK9 inhibitors (evolocumab [C10AX13] and alirocumab [C10AX14]) (Supplementary Table S1). The use of lipid-lowering medication will be estimated as the percentage of patients who received the treatments dispensed in the 6 months before the index date, and during the follow-up period, at 12 and 24 months from the index date.

The duration of the lipid-lowering treatment will be assessed from the date when patients started the treatment to the discontinuation date, which will be defined as the date of the end of the follow-up period (24 months), the patients’ death, or change to another lipid-lowering treatment or the withdrawal of treatment (≥60 days without renewing the initial medication dispensed at the community pharmacy and/or ≥2 prescriptions). Treatment modifications (e.g., doses or the addition of lipid-lowering drugs) will be described, although they are not considered reasons of discontinuation. In case of patients who received a therapy combination, it will be considered that the medication changed if the prescription of any of the molecules was modified. The persistence to the treatment will be calculated at 12 and 24 months. The adherence to the treatment will be estimated as MPR, according to the Professional Society for Health Economics and Outcomes Research (26). It will be calculated as the number of days covered by the dispensed medication divided by the number of treatment days. According to the MPR values at the end of the study, patients will be classified as adherent (MPR ≥80%) or non-adherent (MPR <80%) to the treatment. In addition, the specialty of physicians who prescribed the lipid-lowering treatment for the first time and those who modified the initial treatment will also be reported.

The use of concomitant medications will be obtained in the 6 months before the index date. Concomitant medications include drugs used in diabetes (A10), antithrombotic agents (B01), antihypertensives (C02), agents acting on the renin-angiotensin system (C09), anti-inflammatory and antirheumatic products (M01) and drugs for peptic ulcer and gastroesophageal reflux disease (GERD) (A02B).

Incidence of ASCVD events and mortality

To estimate the clinical effectiveness, the ASCVD events will be assessed during the follow-up period and will be divided into ischemic cardiopathy (angina [CIE-09-CM codes: 411, 413] and AMI [CIE-09-CM codes: 410, 412]), ischemic stroke [CIE-09-CM codes: 433, 434, 436], TIA [CIE-09-CM codes: 435], and PAD (CIE-09-CM codes: 440–441 and 444). All-cause and CV-cause mortality rates will be also estimated.

Use of healthcare resources and costs

The perspective of the Spanish National Health System and society will be considered to estimate healthcare and non-healthcare (indirect) costs during the follow-up period of the study. Healthcare costs are those related to healthcare resources (primary care visits, emergency visits, hospitalizations [annualized rate of hospitalizations and
TABLE 3 Unit costs (year 2021).

| Resources                          | Unit costs (€)* |
|-----------------------------------|-----------------|
| **Healthcare resources**          |                 |
| Medical visits                    |                 |
| Primary care                      | 49.17           |
| Specialized care**                | 101.9           |
| Emergency department              | 258.92          |
| Hospitalization (per day)         | 631.54          |
| Day hospital sessions***          | 4,483.17        |
| **Complementary tests**           |                 |
| Laboratory tests                  | 13.49           |
| Conventional radiology            | 21.47           |
| Computed tomography               | 240.53          |
| Nuclear magnetic resonance        | 315.19          |
| Other diagnostic/therapeutic tests**** | 154.00       |
| Pharmaceutical prescription       | Retail price    |
| Labor productivity (indirect costs)|                 |
| Cost per day of sick leave        | 101.21          |

*Unit costs related to the management of ASCVD were identified.
**It considers Cardiology, Internal medicine, Endocrinology, Vascular, Neurology, Rehabilitation and Geriatrics departments.
***It includes catheterization, angioplasty, endarterectomy/thrombectomy.
****It includes echocardiogram, cardiac exercise stress tests and Holter monitor tests.
ASCVD, arteriosclerotic cardiovascular disease.
Source: Mean of the official tariffs from the Spanish Regions and INE (28).

length of the stay], specialized care visits [Cardiology, Internal medicine, Endocrinology, Vascular Surgeon, Neurology, Rehabilitation and Geriatrics departments], complementary tests [laboratory tests, conventional radiology, computed tomography [CT], nuclear magnetic resonance [NMR], catheterization, angioplasty, endarterectomy and thrombectomy] and medication. Healthcare costs will be calculated considering the frequency of use during the follow-up and their unit cost. Unit costs were estimated as the mean of the official tariffs from the Spanish Regions [when necessary, official tariffs were updated to 2021, according to the gross domestic product (GDP) (27)] (Table 3 and Supplementary Table S2). Drug costs will be quantified using the retail price per pack at the time of dispensing from the community pharmacy (29).

Non-healthcare costs include those associated with lost productivity (days of sick leave due to temporary or permanent disability in the working population [<65 years]) and premature deaths. Productivity losses will be calculated taking into account the number of sick leave days/permanent disability days, the percentage of patients who were on sick leave/permanent disability and the mean salary of the Spanish population, according to the National Institute of Statistics (28) (Table 3). To estimate the non-healthcare costs associated with premature deaths, the total number of lost days per patient (difference between the death age and 65 years, which is the retirement age in Spain) and the average salary of the study population (women: €21,251; men: €27,334) will be considered (28).

The use of healthcare resources and costs will be estimated at 12 and 24 months and costs will be expressed in Euros for the year 2021. Direct non-healthcare costs will not be considered. Healthcare costs and indirect costs will be assessed in patients with ASCVD (5 groups) and FH.

**Statistical analysis**

The statistical analysis will be exploratory and descriptive. The study is not designed to confirm or reject predefined hypotheses. Computer statements (SQL script) will be used to obtain data from the database. Data will be reviewed, using exploratory analyses, checking the distributions, and looking for possible recording or codification mistakes. Data will be validated to guarantee the quality of the results. It is estimated that, based on the inclusion/exclusion criteria, the overall study population will include more than 2,600 patients. The results will be provided for the 6 subgroups of patients previously described.

A statistical univariate analysis for the variables of interest will be carried out. Qualitative data will be described using absolute and relative frequencies (N, %), and quantitative data by using mean and standard deviation (SD) in symmetric distributions and median (interquartile ranges, Q1 – Q3) in asymmetric distributions. In addition, 95% confidence intervals (CI) will be provided to estimate the population parameters. Bivariate analyses (ANOVA and Chi2 tests) will be carried out to compare independent groups regarding statin treatment and LDL levels. The persistence/duration of treatment will be estimated by using a Kaplan-Meier survival analysis (procedure: log-rank test).

Paired statistical tests will be used to estimate the anthropometric/biochemical parameters at the beginning and the end of the study (McNemar/t-Student tests). An ANOVA (generalized lineal model) will be developed to adjust costs for sex, age, Charlson index and time since diagnosis (procedure: marginal means; Bonferroni adjustment). Sub-analyses may be carried out according to new lines of interest. A 0.05 level of statistical significance will be applied in all statistical tests. Data will be analyzed using the SPSS (v27.0) statistical package (SPSS Inc., Chicago, Illinois, USA).

**Discussion**

This study aims to evaluate the treatment patterns and use of healthcare resources of patients with ASCVD and hypercholesterolemia and patients with FH in Spain. It will include patients who suffered an ASCVD event between 01/01/2017 and 31/12/2018, were attended at public primary care centers or hospitals and registered in the BIG-PAC®...
database. The patients’ characteristics, treatment, comorbidities, use of resources and costs will be analyzed during the study period.

Previous observational studies analyzed the management of dyslipidemia in patients with coronary artery disease in Spain. Recently, Alarcón et al. carried out a study in 200 patients with ischemic heart disease during a follow-up period of 5 years. They showed that just 21.7% of them met the optimal therapeutic objective, as they had stopped smoking, were on treatment with statins and aspirin and had LDL levels <70 mg/dL (30). The acute coronary syndrome (ACS) patient pathway project also concluded that the lipid management in these patients is suboptimal, since at least half of them had LDL levels >70 mg/dL and most of their treatments had not been modified during the follow-up period (31). In line with these results, Ribas et al. reported that just 45% of ACS patients reached LDL levels <70 mg/dL in the 122 days after the ACS, and that the use of Masana’s recommendations improved the management and treatment planification in these patients (11). In addition, Ródenas et al. observed that only one third of patients who had suffered a previous myocardial infarction had LDL levels <70 mg/dL during a follow-up period between 2013 and 2018 (32). These analyses considered a relatively small population of patients, but it is expected that our study will include more than 2,600 patients with ASCVD. Therefore, our research will cover different ASCVD events, so that the patients’ characteristics, lipid profiles, treatments, use of resources and costs may be compared.

On the other hand, Redón et al. analyzed the secondary prevention therapies administered during the first year after the hospital admission (due to stroke, myocardial infarction, or coronary revascularization) between 01/01/2011 and 31/12/2013, of 92,432 patients in the Valencian Community (33). Nevertheless, our study will provide more updated information about the management of these patients, using a database representative of the Spanish population (20).

Regarding the heterozygous FH, the SAFEHEART study recorded 2,648 patients in Spain. This recent study estimated the incidence of CV events, the use of lipid-lowering treatments and the achievement of treatment goals among other objectives (34). Due to the design of the Reality study, it will consider a smaller population of patients with FH, but our results will add more information on the use of healthcare resources, and direct healthcare and indirect costs associated with the management of these patients.

The main contributions of this study are the use of real-world data, and the consideration of a wide population of patients with ASCVD. It will provide useful information about the prevalence and incidence rates of ASCVD and FH, the characteristics of these patients and the effectiveness of the treatments currently available. To our knowledge, this will be the first study that estimates the indirect costs associated with ASCVD and FH in Spain. However, our study is not without limitations. First, BIG-PAC® is an administrative database and may have missing information about the study population, particularly if patients have been treated in private centers or public centers that are outside of its area of influence. Second, this study might have the usual limitations of retrospective studies, such as under-recording of diseases (particularly regarding the diagnosis of unstable angina and TIA), the possible inaccuracy of codification, or possible variations in medical practice among professionals. As it was revealed in previous studies, the ICD-9-CM coding system may be poor to identify incident cases of stroke and it should be used in combination with additional data, like physician notes or imaging studies, to confirm the diagnosis of valvular diseases and vascular disorders (35, 36). However, this codification system is widely used in most Spanish hospitals. Third, it should be noted that the BIG-PAC® database may lack variables that could influence our results, such as the socioeconomic level of patients. Finally, since the study lasted until 31/12/2020, our results may be affected by the COVID-19 pandemic. This effect will be estimated in future sub analyses.

In conclusion, this study aims to analyze the treatment patterns and use of healthcare resources ASCVD and FH in Spain. The prevalence of these disorders will also be provided. Due to the high morbidity and mortality associated with these diseases, it is expected that our study will provide useful information for healthcare systems and decision makers to improve the management of these disabling diseases.

Ethics statement

The studies involving human participants were reviewed and approved by Ethics Committee of the Hospital of Terrassa (Barcelona). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author contributions

The study was conceived by AS-M, AS, NM, and JP. Participated and contributed to the design of the study by VB, MC, RC, JG, IE, JMG, IM, JM, VP-C, AS-M, NM, and JP. Data collection and statistical analysis was made by AS-M and AS. The first draft of the manuscript was written by JP. All authors reviewed critically and approved the final version of the submitted manuscript.

Funding

This study was funded by Novartis.
Conflict of interest

This study is a Research collaboration between Atrys Health SA and Novartis Pharmaceuticals. Author VB has received consultancy and lecturing/speaker bureau fees from Almirall, Amgen, Daiichi-Sankyo, Novartis, MSD/Organon, Sanofi, Servier and Mylan/Viatris. Author MC has received consultancy fees for consulting services and as a speaker from Ferrer, Amgen, Daiichi-Sankyo, BMS-Pfizer, Böehringer-Ingelheim, Astra Zeneca, Alexion, Novartis and Lundbeck. Author RC has received lecture fees from Amgen, Daiichi-Sankyo, Ferrer, Mylan, MSD, Organon, Sanofi, Servier and Novartis. She has participated in consultancies for Novartis, Amgen, Sanofi and Servier. She has also received collaborations to scientific or research projects from Amgen, Daiichi-Sankyo, Ferrer, Organon, Servier and Novartis. Author JG declares to have received honoraria for oral presentations and advisory boards, and research grants from Novartis, Amgen, Novartis, Sanofi, and Daiichi. Author IE declares to have received fees for consulting services from Novartis, Servier, and Böehringer-Ingelheim, and to have received fees for services as a speaker from Novartis, Vifor, and Böehringer-Ingelheim. Author JMG declares to have received fees for consulting services from Novartis, Daiichi-Sankyo, Almirall, Sanofi, and Böehringer-Ingelheim, and to have received fees for services as a speaker from Novartis, Daiichi-Sankyo, Almirall, Sanofi, Amgen, Organon, Viatris, Rovi and Menarini. Author JM has received fees for consulting services from Pfizer, Amaryn, Novartis, Daiichi-Sankyo, Servier, Sanofi, and Amgen, and has received fees for services as a speaker from Novartis, Daiichi-Sankyo, Servier, Sanofi, Amgen, Viatris, and Alter. Author VP-C has received fees for consulting and speaker bureau from Almirall, Daiichi-Sankyo, Novartis, Sanofi, Almirall, Rovi, Menarini, Organon.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.966049/full#supplementary-material

References

1. Arnett DK, Blumenthal RS, Albert MA, Bursuker AB, Goldberger ZD, Hahn EL, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. (2019) 140:e256–646. doi: 10.1016/j.circaj.2019.03.010
2. Arrieta F, Iglesias P, Pedro-Botet J, Tíbar FJ, Ortega E, Nubiola A, et al. Diabetes mellitus and cardiovascular risk: Working group recommendations of Diabetes and Cardiovascular Disease of the Spanish Society of Diabetes (SED). (2015) 27:181–92. doi: 10.1016/j.arteri.2014.12.003
3. Mach F, Bairent G, Catapano AL, Koskins KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. (2020) 41:111–88. doi: 10.1093/eurheartj/ehaa455
4. Ma TT, Wong ICK, Man KKC, Chen Y, Crake T, Orkor MA, et al. Effect of evidence-based therapy for secondary prevention of cardiovascular disease: systematic review and meta-analysis. PLoS ONE. (2019) 14:e0210988. doi: 10.1371/journal.pone.0210988
5. Patnode CD, Evans CV, Senger CA, Redmond N, Lin JS. Behavioral counseling to promote a healthful diet and physical activity for cardiovascular disease prevention in adults without known cardiovascular disease risk factors: updated evidence report and systematic review for the US preventive services task force. JAMA. (2017) 318:175–93. doi: 10.1001/jama.2017.3303
6. Berman AN, Blankstein R. Optimizing dyslipidemia management for the prevention of cardiovascular disease: a focus on risk assessment and therapeutic options. Curr Cardiovasc Rep. (2019) 21:110. doi: 10.1007/s11886-019-1175-z
7. Coll PP, Roche V, Olsen JS, Voit JH, Bowen E, Kumar M. The prevention of cardiovascular disease in older adults. J Am Geriatr Soc. (2020) 68:1098–106. doi: 10.1111/jgs.16553
8. Katzmann JL, Laufs U. New insights in the control of low-density lipoprotein cholesterol to prevent cardiovascular disease. Curr Cardiovasc Rep. (2019) 21:69. doi: 10.1007/s11886-019-1159-z
9. Vallejo-Vaz AI, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, et al. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis. (2019) 288:85–93. doi: 10.1016/j.atherosclerosis.2019.07.008
10. Cholesterol Treatment Trials’ (CCT) Collaboration, Baigent C, Blackwell L, Emberson J, Hollander LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. (2010) 376:1670–81. doi: 10.1016/S0140-6736(10)61350-5
11. Ribas N, Recasens L, Pérez S, Bazán V, Pedro-Botet J, Ruiz S, et al. New rational approach to reach LDL-cholesterol concentration objectives after an acute coronary syndrome. Clin Invest Arterioscler. (2019) 31:93–100. doi: 10.1016/j.art.2019.05.001
12. Masana L, Plana N. Update of planning tables of cholesterol-lowering therapy orientated to achieve LDL therapeutic targets. Clin Invest Arterioscler. (2015) 27:138–43. doi: 10.1016/j.art.2015.02.004
13. Lloyd-Jones DM, Morriss PB, Ballantyne CM, Birtcher KR, Daly DD, DePalma SM, et al. 2017 Focused Update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the american college of cardiology task force on expert consensus decision pathways. J Am Coll Cardiol. (2017) 70:1785–100. doi: 10.1016/j.jacc.2017.07.745
14. Kotseva K, De Backer G, De Bacquier D, Rydén L, Hoñ E, Grobbe L, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. (2019) 26:824–35. doi: 10.1177/2047487318825350
15. Ray KK, Molenmans B, Schoonen WM, Giusas P, Bray S, Kiru G, et al. EU-Wide Cross-sectional observational study of lipid-modifying therapy use in

Frontiers in Cardiovascular Medicine

08

frontiersin.org
secondary and primary care: the DA VINCI study. *Eur J Prev Cardiol.* (2021) 28:1279–89. doi: 10.1093/eurjpc/zwa407

16. Mahatta D, Rodriguez F, Jneid H, Levine GN, Virani SS. Improving adherence to cardiovascular guidelines: realistic transition from paper to patient. *Expert Rev Cardiovasc Ther.* (2020) 18:41–51. doi: 10.1080/14779072.2020.1717335

17. Li T, Jiang S, Ni B, Cui Q, Liu Q, Zhao H. Discontinued drugs for the treatment of cardiovascular disease from 2016 to 2018. *Int J Mol Sci.* (2019) 20:4513. doi: 10.3390/ijms20184513

18. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Big-Pac. (2021). Available online at: http://www.encepp.eu/encepp/viewResource.htm?id=29236 (accessed April 13, 2021).

19. Boletín Oficial del Estado. Ley Orgánica 3/2018, de 5 de diciembre, de Protección de Datos Personales y garantía de los derechos digitales. (2018). Available online at: https://www.boe.es/buscar/doc.php?id=BOE-A-2018-16673 (accessed April 13, 2021).

20. Sicras-Mainar A, Enriquez JL, Hernández I, Sicras-Navarro A, Aymerich T, Leon M. PMU/146 Validation and representativeness of the Spanish BIG-PAC database: integrated computerized medical records for research into epidemiology, medicines and health resource use (real world evidence). *Value in Health.* (2019) 22:S734. doi: 10.1016/j.jval.2019.09.1764

21. Ministerio de Sanidad, Consumo y Bienestar Social. International Classification of Diseases (9th edition) Clinical Modification (ICD-09-CM). (2021). Available online at: https://eciemaps.mscbs.gob.es/cciemaps/browser/index_9_mc.html (accessed April 13, 2021).

22. Escobar C, Anguita M, Arrarte V, Barrios V, Céspedes-Atienza J, et al. Recommendations to improve lipid control Consensus document of the Spanish Society of Cardiology. *Rev Esp Cardiol (Engl Ed).* (2020) 73:161–7. doi: 10.1016/j.rec.2019.08.012

23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* (1987) 40:373–83. doi: 10.1016/0021-9681(87)90171-8

24. Deyo RA, Cherkin DC, Cordier M. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol.* (1992) 45:613–9. doi: 10.1016/0895-4356(92)90133-8

25. World Health Organization (WHO). The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC/DDD). Available online at: https://whqlibdoc.who.int/standards/classifications/other-classifications/the-anatomical-therapeutic-chemical-classification-system-with-defined-daily-doses (accessed April 8, 2021).

26. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. *JAMA.* (2002) 288:455–61. doi: 10.1001/jama.288.4.455

27. Instituto Nacional de Estadística. Cálculo de variaciones del Índice de Precios de Consumo. INE. (2016). Available online at: https://www.ine.es/varipc/verVariaciones.do?idmesfin=1&anyofin=2016&capsel=4563&capfin=4563 (accessed April 8, 2021).

28. Instituto Nacional de Estadística. Ganancia media laboral por edad y sexo. Available online at: https://www.ine.es/dyn/inebase/index.htm?padre=4563&capsel=4563 (accessed April 13, 2021).

29. Alarcón MAM, Mas MT, Morales-Gabardino JA, Buitrago-Ramírez F. Prevalencia y grado de control de los factores de riesgo cardiovascular en pacientes con cardiopatía isquémica adscritos a un centro de salud urbano. *Rev Esp Salud Públic.* (2021) 95:6.

30. Landmesser U, Pierillo A, Farnier M, Lukema JW, Lawf U, Mach F, et al. Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes. The ACS patient pathway project. *Atheroscler Suppl.* (2020) 42:e49–58. doi: 10.1016/j.atherosclerosissup.2021.01.009

31. Redón J, Usó R, Trillo JL, López C, Morales-Olivas F, Navarro J, et al. Number of drugs used in secondary cardiovascular prevention and late survival in the population of Valencia Community, Spain. *Int J Cardiol.* (2019) 293:260–5. doi: 10.1016/j.ijcard.2019.05.071

32. Pérez de. Isla L, Arroyo-Olivares R, Alonso R, Muñiz-Grimalvo O, Díaz-Díaz JL, Zambón D, et al. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry. *Rev Esp Cardiol (Engl Ed).* (2020) 73:828–34. doi: 10.1016/j.recesp.2019.10.013

33. Birman-Deych E, Waterman AD, Yan Y, Nilsaen DS, Radford MJ, Gage BF. Accuracy of ICD-9-CM Codes for Identifying Cardiovascular and Stroke Risk Factors. *Med Care.* (2003) 41:480–5. doi: 10.1097/01.mlr.0000106417.39497.a9

34. Goldstein LB. Accuracy of ICD-9-CM coding for the identification of patients with acute ischemic stroke. *Stroke.* (1998) 29:1602–4. doi: 10.1161/01.STR.29.8.1602